PAXLOVID from Pfizer
Pfizer’s PAXLOVID received EUA approval for use in COVID-19 positive patients ages 12 and up with a high risk for progression to severe COVID-19. The PAXLOVID prescription includes nirmatrelvir and ritonavir tablets, which must be co-administered.
To achieve the best outcome, start treatment as soon as possible after a positive diagnosis and within five days of the start of symptoms. PAXLOVID may cause drug interactions with certain other medications.
MOLNUPIRAVIR from Merck
Merck’s MOLNUPIRAVIR also received EUA approval for use in COVID-19 positive patients ages 18 and up with a high risk for progression to severe COVID-19. This solution applies when alternative COVID-19 treatment is not accessible or clinically appropriate.
To achieve the best outcome, start treatment as soon as possible after a positive diagnosis and within five days of the start of symptoms. Based on current and limited data, no drug interactions have been identified.